Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery

• Published in: Journal of controlled release 2015-08, Vol.211, p.118-133
• Main Authors: Vaidya, Bhuvaneshwar, Gupta, Vivek
• Format: Article
• Language: English
• Subjects: Animals; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - metabolism; Cardiovascular disorders; Drug Delivery Systems - trends; Endothelial progenitor cells; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - metabolism; Liposomes; miRNA; Molecular pathways; Molecular Targeted Therapy - trends; Nanocarriers; Nanoparticles; Nanoparticles - administration & dosage; Nanotechnology; Protein Kinase Inhibitors - administration & dosage; Pulmonary arterial hypertension; ROCK inhibitors; Tyrosine kinase
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2015.05.287

Pulmonary arterial hypertension (PAH) is a cardiopulmonary disorder characterized by increased blood pressure in the small arterioles supplying blood to lungs for oxygenation. Advances in understanding of molecular and cellular biology techniques have led to the findings that PAH is indeed a cascade of diseases exploiting multi-faceted complex pathophysiology, with cellular proliferation and vascular remodeling being the key pathogenic events along with several cellular pathways involved. While current therapies for PAH do provide for amelioration of disease symptoms and acute survival benefits, their full therapeutic potential is hindered by patient incompliance and off-target side effects. To overcome the issues related with current therapy and to devise a more selective therapy, various novel pathways are being investigated for PAH treatment. In addition, inability to deliver anti-PAH drugs to the disease site i.e., distal pulmonary arterioles has been one of the major challenges in achieving improved patient outcomes and improved therapeutic efficacy. Several novel carriers have been explored to increase the selectivity of currently approved anti-PAH drugs and to act as suitable carriers for the delivery of investigational drugs. In the present review, we have discussed potential of various novel molecular pathways/targets including RhoA/Rho kinase, tyrosine kinase, endothelial progenitor cells, vasoactive intestinal peptide, and miRNA in PAH therapeutics. We have also discussed various techniques for site-specific drug delivery of anti-PAH therapeutics so as to improve the efficacy of approved and investigational drugs. This review will provide gainful insights into current advances in PAH therapeutics with an emphasis on site-specific drug payload delivery. [Display omitted]